ATHENS, Greece, via ETELIGIS INC., 02/17/2015 – – HCi Viocare (the "Company") (OTCQB: VICA), today announced that they will be unveiling their smart diabetic insole at the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Paris on the 18th and 19th of February.
This low-cost, ground-breaking device can wirelessly relay foot pressure and shear information to a smartphone in real time. It is intended to help people with diabetes monitor their condition and help them prevent diabetic foot ulcers, thereby reducing the number of related amputations.
Up to 70 percent of diabetic patients will have nerve damage in their feet1, and up to 25 percent will develop a diabetic foot ulcer2, leading to many thousands of preventable amputations each year. Worldwide, every 20 seconds a foot is amputated due to diabetes3.
Dr Christos Kapatos, Chief Technology Officer, and Heleen Kist, Chief Operating Officer, will be engaging with companies in the diabetes monitoring market at the ATTD Conference to find a suitable partner for the commercialisation of the newly developed smart insole.
Interested parties wishing to meet the HCi Viocare team at the ATTD conference can contact Ms. Kist on h.kist.
1. Source: National Diabetes Information Clearinghouse
2. Source: Singh N, Armstrong DG, Lipsky BA: Preventing foot ulcers in patients with diabetes. JAMA 293:217-228, 2005
3. Source: International Diabetes Federation
About HCi Viocare
HCi Viocare has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health & wellbeing areas, for licensing to established industry participants.
The company is listed on the OTC Markets in the USA, has its executive office in Athens, Greece and R&D centre in Glasgow, UK.
On behalf of the Board of Directors of HCi Viocare
Chief Executive Officer and President
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or in finding partners for commercialisation of its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
For further information about HCi Viocare please visit the Company’s website at http://www.viocare.eu
Chief Executive Officer and President
SOURCE: HCi Viocare